Chugai’s 2013 Financial Results: Cancer Therapy Sales Up 10.4%
This article was originally published in PharmAsia News
Executive Summary
Sales of Chugai’s flagship cancer drug Avastin (bevacizumab) increased by 15% in 2013 compared to the previous year, with overall oncology sales increasing by 10%.